Key result
VA-ECMO fails to reduce mortality in AMI-related cardiogenic shock.
Why the study?
Does VA-ECMO reduce mortality in patients with Acute Myocardial Infarction-related Cardiogenic Shock?
RCT
Does VA-ECMO reduce mortality in patients with Acute Myocardial Infarction-related Cardiogenic Shock?
The ECLS-SHOCK trial failed to show a mortality benefit for VA-ECMO in AMI-CS, suggesting liberal use should be avoided, though high crossover and illness severity complicate interpretation.
ECLS-SHOCK is the largest randomized control trial on Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) in Acute Myocardial Infarction-related Cardiogenic Shock (AMI-CS). Unfortunately, ECLS-SHOCK failed to demonstrate a reduction of mortality in AMI-CS with VA-ECMO. Interpretation of these findings must account for frequent crossover to VA-ECMO or other temporary mechanical circulatory support (tMCS) devices in the control group, as well as the exceptionally high severity of illness among participants. We detail here point by point what could explain the outcomes and the unanswered questions. In the light of these results, a liberal use of VA-ECMO might be avoided. Further trials are needed to refine patient selection criteria and determine the optimal timing ("sweet-spot") for VA-ECMO implementation. Current practice and future guidelines will have to take in count ECLS-SHOCK results.
No takes yet. Share an insight, caveat, or question.
Théry et al. (2025) conducted an RCT in Acute Myocardial Infarction-related Cardiogenic Shock (AMI-CS). Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) vs. control group was evaluated on mortality. Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) failed to demonstrate a reduction of mortality in Acute Myocardial Infarction-related Cardiogenic Shock.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: